Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Mould species represent the pathogens most commonly associated with invasive fungal disease in patients with haematological malignancies and patients of haemopoietic stem cell transplants. Invasive mould infections in these patient populations, particularly in the setting of neutropenia, are associated with high morbidity and mortality, and significantly increase the complexity of management. While Aspergillus species remain the most prevalent cause of invasive mould infections, Scedosporium and Fusarium species and the Mucormycetes continue to place a significant burden on the immunocompromised host. Evidence also suggests that infections caused by rare and emerging pathogens are increasing within the setting of broad-spectrum antifungal prophylaxis and improved survival times placing immunosuppressed patients at risk for longer. These guidelines present evidence-based recommendations for the antifungal management of common, rare and emerging mould infections in both adult and paediatric populations. Where relevant, the role of surgery, adjunctive therapy and immunotherapy is also discussed.
['Blyth|C C|CC|', 'Gilroy|N M|NM|', 'Guy|S D|SD|', 'Chambers|S T|ST|', 'Cheong|E Y|EY|', 'Gottlieb|T|T|', 'McGuinness|S L|SL|', 'Thursky|K A|KA|']
D000935:Antifungal Agents D001228:Aspergillosis D032921:Consensus D004334:Drug Administration Schedule D025141:Drug Resistance, Fungal D019317:Evidence-Based Medicine D060585:Fusariosis D019337:Hematologic Neoplasms D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D016867:Immunocompromised Host D009503:Neutropenia D009894:Opportunistic Infections D017410:Practice Guidelines as Topic D065129:Pre-Exposure Prophylaxis
antifungal therapy aspergillosis emerging fungal infection invasive mould disease mucormycosis